Bank of America Corp DE cut its holdings in shares of LivaNova PLC (NASDAQ: LIVN) by 30.6% in the fi

LivaNova (NASDAQ: LIVN - Get Free Report) and Dynatronics (NASDAQ: DYNT - Get Free Report) are both

LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin g

Needham analyst Mike Matson maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price targ

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

LivaNova NASDAQ: LIVN reported record quarterly revenue and adjusted earnings per share for the seco

While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performe

LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a

LivaNova (LIVN) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Est

LivaNova (NASDAQ:LIVN) raises FY2026 Adj EPS guidance from $4.20-$4.30 to $4.30-$4.40 vs $4.25 analy

LivaNova (NASDAQ:LIVN) reported quarterly earnings of $1.26 per share which beat the analyst consens

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading m

Amundi cut its position in shares of LivaNova PLC (NASDAQ: LIVN) by 3.5% during the undefined quarte

Bank of New York Mellon Corp lessened its holdings in shares of LivaNova PLC (NASDAQ: LIVN) by 34.3%

GenAI creates new opportunities for ISRG, ALC and LIVN, even as regulatory, inflation and industry h

Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the

LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a

Top Wall Street analysts changed their outlook on top names. See the latest analyst ratings and cove

Freedom Capital Markets analyst Keith Hinton initiates coverage on LivaNova (NASDAQ:LIVN) with a

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical techno

Keybanc analyst Brett Fishbin maintains LivaNova (NASDAQ:LIVN) with a Overweight and raises the p

LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical techno

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical techno

LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript

LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcri

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appoin

Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the

Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the

Baird analyst David Rescott maintains LivaNova (NASDAQ:LIVN) with a Outperform and lowers the pri

Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised

Full-Year 2026 GuidanceLivaNova now expects full-year 2026 revenue to grow between 7.0% and 8.0% (ve

Full-Year 2026 GuidanceLivaNova now expects full-year 2026 revenue to grow between 7.0% and 8.0% (ve

LivaNova (NASDAQ:LIVN) reported quarterly earnings of $0.98 per share which beat the analyst consens

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that the jo

– First and only hypoglossal nerve stimulation therapy approved in the U.S. without complete concent

Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the

Needham analyst Mike Matson maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price targ

LivaNova (NASDAQ:LIVN) is looking for FY2026 Adj EPS of $4.15-$4.25 vs $4.13 analyst estimate. sees

LivaNova (NASDAQ:LIVN) reported quarterly earnings of $0.86 per share which beat the analyst consens

Orrum's CŌRE Insights™ analytics platform will be available through an automatic integration for

Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the

Stifel analyst Rick Wise maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target

Keybanc analyst Brett Fishbin initiates coverage on LivaNova (NASDAQ:LIVN) with a Overweight rati